Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mesothelioma, drawn from the whole corpus: 43 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Sarcomatoid subtype.
No early detection despite known exposure.
Even the best first-line regimens give a median survival under two years; the tail of long survivors on immunotherapy is what to build on.
Epithelioid disease gains little from immunotherapy over chemotherapy; no predictive biomarker beyond histology.
No approved targeted therapy despite recurrent BAP1, CDKN2A/MTAP, and NF2 alterations.
Once immunotherapy has been used first line, the second-line options are platinum-pemetrexed rechallenge, gemcitabine or vinorelbine, none with a randomised survival trial behind it in that sequence; mesothelin CAR-T, mesothelin ADCs and engagers, and PRMT5 inhibitors for MTAP-deleted tumours are the trials addressing it.
Surgery's role is now unclear for the small group of early, epithelioid, node-negative patients.
Response assessment is hard (modified RECIST for pleural rind); trials are small and slow.
Asbestos is still produced and used in several large countries; incidence will rise there for decades.
Peritoneal and rarer sites lack dedicated evidence.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 31 changes by month →When this page itself was last checked or edited.
CT and PET/CT; thoracoscopic biopsy with IHC panel (calretinin, WT1, D2-40; BAP1 and MTAP loss support malignancy); histology and BAP1/MTAP status recorded for treatment planning. (NCCN MPM guideline)
Stopped early; primary endpoint not met.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
OS not significantly improved overall; benefit in non-epithelioid subgroup.